ZYVERSA THERAPEUTICS, INC. — Key Metrics
2 years of history · ending 2024-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$-8
Book Value Per Share
$8
Free Cash Flow Per Share
$-7
Revenue Per Share
$-0
OCF Per Share
$-7
Return on Equity
-96.1%
Return on Assets
-44.1%
Return on Invested Capital
-73.7%
Current Ratio
0.15
Quick Ratio
0.15
Asset Turnover
-0.01
R&D / Revenue
-659.3%
SBC / Revenue
-261.5%
Working Capital
$-10M
Net Current Asset Value
$-10M
Invested Capital
$9M
OCF / Net Income
0.80
FCF / Net Income
0.80
Accruals Ratio (Sloan)
-9.2%
Net Debt
—
Net Debt / EBITDA
—
Tangible Common Equity
$9M
TCE / Total Assets
41.3%
NOPAT
$-7M
Cash ROIC
-76.8%
WC / Revenue
3526.1%
Reinvestment Rate
0.1%
Asset Growth vs Revenue Growth
59142.6%
Stock Price (FY-end)
$1
Market Cap
$1M
P/S Ratio
-4.36
P/B Ratio
0.14
P/TB Ratio
0.14
Enterprise Value
$1M
EV / Sales
-4.36
FCF Yield
-639.1%
Shareholder Yield
-60.0%
R&D Yield
151.2%
Shares Variation (YoY)
1038.5%
Beta (5Y)
0.54
Cost of Equity
7.2%
52W High
$11
52W Low
$1
Trailing Return 1Y
-88.2%
F-Score (Piotroski)
2.00
Z-Score (Altman)
-9.63
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.